Title |
Optimizing tumor-targeting chimeric antigen receptor T cells in B-cell lymphoma patients
|
---|---|
Published in |
Immunotherapy, December 2011
|
DOI | 10.2217/imt.11.135 |
Pubmed ID | |
Authors |
Maher Gandhi, Kimberley Jones |
Abstract |
Evaluation of: Savoldo B, Ramos CA, Liu E et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121(5), 1822-1826 (2011). Chimeric antigen receptor (CAR)-T cells are promising antitumor immunotherapies. However, there are limited reports of persistence, tumor-homing and clinical efficacy in cancer patients. Savoldo and colleagues used a novel approach to compare the use of first- and second-generation tumor-specific CAR-T cells in six B-cell lymphoma patients. They provide one of the first comparisons in human subjects and demonstrate the superiority of second-generation CAR-T cells to expand, survive and home to the tumor site. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 9% |
Unknown | 10 | 91% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Professor > Associate Professor | 2 | 18% |
Researcher | 2 | 18% |
Student > Ph. D. Student | 1 | 9% |
Student > Doctoral Student | 1 | 9% |
Student > Bachelor | 1 | 9% |
Other | 1 | 9% |
Unknown | 3 | 27% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 3 | 27% |
Agricultural and Biological Sciences | 3 | 27% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 9% |
Unknown | 4 | 36% |